Kim A. Papp

Mar 22, 2024 | dermatologytimes.com | Emma Andrus |Kim A. Papp

The phase 2 clinical trial of ESK-001, a TYK2 inhibitor, for treating moderate-to-severe plaque psoriasis, met its primary endpoint of PASI 75 at week 12 compared to placebo, along with key secondary efficacy endpoints across all relevant doses, according to data presented at the American Academy of Dermatology Annual Meeting in San Diego, California. In the STRIDE trial, dose-dependent responses were observed, with maximal efficacy achieved at the highest dose of 40 mg twice daily.

Mar 7, 2024 | onlinelibrary.wiley.com | Bruce E. Strober |Andrew Blauvelt |Richard Warren |Kim A. Papp

INTRODUCTION The Janus kinase (JAK)-signal transducer and activator of transcription pathways play a major role in cytokine signalling in normal cellular processes and in immune-mediated diseases such as psoriasis.1, 2 JAK1,2,3 inhibitors are efficacious in patients with moderate-to-severe plaque psoriasis; however, JAK1,2,3 inhibitors are also associated with creatine phosphokinase (CPK) elevations, hyperlipidaemia and minimal hematologic abnormalities.3, 4 Therefore, it is important to...

Dec 20, 2023 | jamanetwork.com | Kim A. Papp |Kenneth Gordon |Bruce E. Strober |Joe Zhuo

Key PointsQuestion  What constituted meaningful within-patient score improvement on the Psoriasis Symptoms and Signs Diary (PSSD) in a phase 3 trial among patients with psoriasis?

Oct 18, 2023 | bpno.dk | Kim A. Papp

oktober 2023 Kim Papp presents in this MEDtalk results from the phase III POETYK PSO-1 and POETYK PSO-2 trials related to the treatment of plaque psoriasis with the drug deucravacitinib. The trial showed improvement in all domains related to the signs and symptoms, and the improvement was sustained over time. In concordance with the clinical practice, the data supports the effectiveness of deucravacitinib in treating chronic plaque psoriasis.

Aug 1, 2023 | pericles.pericles-prod.literatumonline.com | Emma Guttman-Yassky |Jonathan I. Silverberg |Diamant Thaçi |Kim A. Papp

Abstract Background Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic eczematous lesions. The effect of treatment withdrawal after response to upadacitinib oral treatment is not fully characterized. Objectives Assess the effect of upadacitinib withdrawal on skin clearance and itch improvement in adult patients with moderate-to-severe AD and evaluate the kinetics of recovery on rescue treatment.